Vorinostat, an approved lymphoma treatment sold as Zolinza, was found to ease both neurological and non-neurological symptoms in a mouse model of Rett syndrome in a new study. When an oral formulation of vorinostat was administered after symptom onset, the drug was even more effective than Daybue (trofinetide), the only approved treatment for Rett, which […] The post Use of cancer drug vorinostat shown to ease symptoms in Rett mice appeared first on Rett Syndrome News.
